Cassava Sciences (NASDAQ:SAVA - Get Free Report)'s stock had its "neutral" rating reissued by HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $2.00 target price on the stock. HC Wainwright's price objective would suggest a potential upside of 21.21% from the stock's current price.
Cassava Sciences Stock Down 2.9 %
Shares of SAVA traded down $0.05 during midday trading on Tuesday, reaching $1.65. 1,449,762 shares of the stock were exchanged, compared to its average volume of 2,969,006. Cassava Sciences has a twelve month low of $1.63 and a twelve month high of $42.20. The company has a market cap of $79.71 million, a P/E ratio of -1.20 and a beta of -1.24. The stock's 50 day simple moving average is $2.49 and its 200 day simple moving average is $12.00.
Cassava Sciences (NASDAQ:SAVA - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.68) by $0.11. As a group, analysts predict that Cassava Sciences will post -3.97 earnings per share for the current year.
Institutional Trading of Cassava Sciences
Institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC raised its stake in Cassava Sciences by 4.3% in the third quarter. Geode Capital Management LLC now owns 1,008,593 shares of the company's stock valued at $29,688,000 after purchasing an additional 41,289 shares in the last quarter. Two Sigma Advisers LP bought a new stake in Cassava Sciences during the fourth quarter worth $1,432,000. Two Sigma Investments LP increased its stake in shares of Cassava Sciences by 679.1% in the 4th quarter. Two Sigma Investments LP now owns 562,082 shares of the company's stock valued at $1,327,000 after purchasing an additional 489,936 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Cassava Sciences by 2.7% during the 4th quarter. Northern Trust Corp now owns 406,562 shares of the company's stock worth $959,000 after buying an additional 10,782 shares in the last quarter. Finally, Tidal Investments LLC bought a new stake in shares of Cassava Sciences during the 3rd quarter worth $11,036,000. 38.05% of the stock is currently owned by institutional investors.
About Cassava Sciences
(
Get Free Report)
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Read More
Before you consider Cassava Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cassava Sciences wasn't on the list.
While Cassava Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
